Title |
Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China
|
---|---|
Published in |
Frontiers in immunology, September 2018
|
DOI | 10.3389/fimmu.2018.02066 |
Pubmed ID | |
Authors |
Qiao Huang, Jingqi Wang, Yifan Zhou, Hui Yang, Zhanhang Wang, Zhenwen Yan, Youming Long, Jia Yin, Huiyu Feng, Caixia Li, Zhengqi Lu, Xueqiang Hu, Wei Qiu |
Abstract |
Objective: To evaluate the efficacy and safety of low-dose mycophenolate mofetil (MMF, 1,000 mg/day) treatment of neuromyelitis optica spectrum disorders (NMOSDs). Methods: This study was a multicenter, open, prospective, follow-up clinical trial. The data include retrospective clinical data from the pretreatment phase and prospective data from the post-treatment phase. From September 2014 to February 2017, NMOSD patients seropositive for aquaporin 4-IgG (AQP4-IgG) were treated with low-dose MMF. Results: Ninety NMOSD patients were treated with MMF for a median duration of 18 months (range 6-40 months). The median annual recurrence rate (ARR) decreased from 1.02 before treatment to 0 (P < 0.0001) after treatment, and the Expanded Disability Status Scale (EDSS) score decreased from 4 to 3 (P < 0.0001). The EDSS score was significantly lower (P = 0.038) after the first 90 days of treatment. The serum AQP4-IgG titer decreased in 50 cases (63%). The median Simple McGill pain score (SF-MPQ) was reduced in 65 patients (88%) with myelitis from 17 (range 0-35) to 11 (range 0-34) after treatment (P < 0.0001). The median Hauser walking index (Hauser Walk Rating Scale) was reduced from 2 (range 1-9) before treatment to 1 (range 0-7) after treatment (P < 0.0001). Adverse events were documented in 43% of the patients, and eight patients discontinued MMF due to intolerable adverse events. Fourteen (16%) of the total patients discontinued MMF after our last follow-up for various reasons and switched to azathioprine or rituximab. Conclusion: Low-dose MMF reduced clinical relapse and disability in NMOSD patients in South China. However, some patients still suffered from adverse events at this dosage. www.ClinicalTrials.gov, identifier : NCT02809079. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 37 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 6 | 16% |
Student > Postgraduate | 5 | 14% |
Researcher | 4 | 11% |
Student > Bachelor | 3 | 8% |
Student > Ph. D. Student | 3 | 8% |
Other | 6 | 16% |
Unknown | 10 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 32% |
Neuroscience | 7 | 19% |
Nursing and Health Professions | 2 | 5% |
Arts and Humanities | 1 | 3% |
Environmental Science | 1 | 3% |
Other | 2 | 5% |
Unknown | 12 | 32% |